Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription

Articles published in BJU Int

Retrieve available abstracts of 199 articles:
HTML format

Single Articles

    August 2022
  1. SCHNEIDER A, Bulafka J, Arisi MF, Li L, et al
    Case of the month from the Thomas Jefferson Sidney Kimmel medical college, Philadelphia, USA. Prostatic abscess and advanced prostate cancer: considering malignancy in the differential diagnosis.
    BJU Int. 2022;130:181-185.

    July 2022
  2. WILLIAMS IS, Perera S, Murphy DG, Corcoran NM, et al
    Active surveillance versus enzalutamide for low-risk prostate cancer- was it really a trial we needed?
    BJU Int. 2022 Jul 25. doi: 10.1111/bju.15860.

  3. RUSHWORTH LK, Loveridge C, Salji M, MacLeod M, et al
    Phase II Proof of Concept Study of Atorvastatin in Castration Resistant Prostate Cancer.
    BJU Int. 2022 Jul 18. doi: 10.1111/bju.15851.
    PubMed     Abstract available

  4. FDA approves new agent for the treatment of metastatic prostate cancer.
    BJU Int. 2022;130:3-4.

  5. PARRY MG, Skolarus TA, Nossiter J, Sujenthiran A, et al
    Urinary incontinence and use of incontinence surgery after radical prostatectomy: a national study using patient-reported outcomes.
    BJU Int. 2022;130:84-91.
    PubMed     Abstract available

  6. SETIA SA, Smith J, Cendo D, Yoder J, et al
    Outcomes of freehand transperineal prostate biopsy with omission of antibiotic prophylaxis.
    BJU Int. 2022;130:54-61.
    PubMed     Abstract available

    June 2022
  7. DJURHUUS SS, Simonsen C, Toft BG, Thomsen SN, et al
    Exercise Training to Increase Tumor NK Cell Infiltration in Men with Localized Prostate Cancer: an RCT.
    BJU Int. 2022 Jun 26. doi: 10.1111/bju.15842.
    PubMed     Abstract available

  8. AGGARWAL A, Han L, Tree A, Lewis D, et al
    Impact of centralisation of prostate cancer services on the choice of radical treatment.
    BJU Int. 2022 Jun 20. doi: 10.1111/bju.15830.
    PubMed     Abstract available

  9. SUSHENTSEV N, Barrett T, Warren AY, Gnanapragasam VJ, et al
    How and when should radiologists report T-staging on MRI in patients with prostate cancer?
    BJU Int. 2022 Jun 13. doi: 10.1111/bju.15824.

  10. HARVEY M, Ong WL, Chao M, Udovicich C, et al
    Comprehensive review of hydrogel spacers prior to radiation therapy for prostate cancer.
    BJU Int. 2022 Jun 10. doi: 10.1111/bju.15821.
    PubMed     Abstract available

  11. LANGLEY S, Eden C, Perry M, Patil K, et al
    Robot-assisted salvage seminal vesicle excision for isolated recurrence after low-dose-rate prostate brachytherapy.
    BJU Int. 2022;129:731-736.
    PubMed     Abstract available

    Sensible government decisions on funding for imaging can change practice and deliver better care for men with prostate cancer.
    BJU Int. 2022;130 Suppl 1:4.

  13. PERRY E, Talwar A, Taubman K, Ng M, et al
    Pathological predictors of (18) F-DCFPyL prostate-specific membrane antigen-positive recurrence after radical prostatectomy.
    BJU Int. 2022;130 Suppl 1:28-36.
    PubMed     Abstract available

    May 2022
  14. O'BRIEN JS, McVey A, Kelly BD, Jenjitranant P, et al
    PSMA PET-CT Funding Grants Free Access to Superior Staging for Australian Men with Prostate Cancer.
    BJU Int. 2022 May 16. doi: 10.1111/bju.15773.

  15. RAHOTA RG, Diamand R, Malavaud B, Fiard G, et al
    Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
    BJU Int. 2022;129:621-626.
    PubMed     Abstract available

  16. HAYNE D, Grummet J, Espinoza D, McCombie SP, et al
    'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501).
    BJU Int. 2022;129:591-600.
    PubMed     Abstract available

    April 2022
  17. NATHAN A, Morris M, Parry MG, Berry B, et al
    Interventions for obstructive uropathy in advanced prostate cancer: a population-based study.
    BJU Int. 2022 Apr 29. doi: 10.1111/bju.15766.
    PubMed     Abstract available

  18. VAN RIEL LAMJG, Geboers B, Kabaktepe E, Blazevski A, et al
    Outcomes of Salvage Radical Prostatectomy after initial IRE Treatment for Recurrent Prostate Cancer.
    BJU Int. 2022 Apr 27. doi: 10.1111/bju.15759.
    PubMed     Abstract available

  19. BOKU H, Kaneko M, Yamada Y, Morinaga Y, et al
    Microwave for focal therapy of prostate cancer: Non-clinical study and exploratory clinical trial.
    BJU Int. 2022 Apr 18. doi: 10.1111/bju.15749.
    PubMed     Abstract available

  20. LANE JA, Donovan JL, Young GJ, Davis M, et al
    Functional and quality of life outcomes of localised prostate cancer treatments (ProtecT study).
    BJU Int. 2022 Apr 3. doi: 10.1111/bju.15739.
    PubMed     Abstract available

  21. CHASE EC, Bryant AK, Sun Y, Jackson WC, et al
    Development and Validation of a Life Expectancy Calculator for U.S. Prostate Cancer Patients.
    BJU Int. 2022 Apr 3. doi: 10.1111/bju.15740.
    PubMed     Abstract available

  22. PTASZNIK G, Papa N, Kelly BD, Thompson J, et al
    High PSMA PET SUVmax in PI-RADS 4 or 5 men confers a high probability of significant prostate cancer.
    BJU Int. 2022 Apr 1. doi: 10.1111/bju.15736.

  23. Prostate cancer and ethnicity, personalised treatment for renal masses and oral testosterone for hypogonadism.
    BJU Int. 2022;129:422.

  24. LUZZAGO S, Piccinelli ML, Mistretta FA, Bianchi R, et al
    Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates.
    BJU Int. 2022;129:524-533.
    PubMed     Abstract available

    March 2022

  25. New guidance regarding the diagnosis and risk stratification of patients with prostate cancer.
    BJU Int. 2022;129:304-305.

  26. KLEIN RJ
    Polygenic risk scores and prostate cancer screening: a recipe for more overdiagnosis?
    BJU Int. 2022;129:271.

  27. FERRARO S, Biganzoli EM
    Association between total prostate-specific antigen (tPSA), free/tPSA, and prostate cancer mortality.
    BJU Int. 2022;129:418.

  28. MARTIN RM, Dixon P, Turner E, Keeney E, et al
    Contribution of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) to the ongoing debate on the value of prostate cancer screening.
    BJU Int. 2022;129:269-270.

  29. TEYATEETI A, Grossman C, Kollmeier MA, Fiasconaro M, et al
    Influence of hydrogel spacer placement with prostate brachytherapy on rectal and urinary toxicity.
    BJU Int. 2022;129:337-344.
    PubMed     Abstract available

  30. BJORKLUND J, Stattin P, Ronmark E, Aly M, et al
    The 90-day cause-specific mortality after radical prostatectomy: a nationwide population-based study.
    BJU Int. 2022;129:318-324.
    PubMed     Abstract available

  31. ZHAO J, Sun G, Zhu S, Dai J, et al
    Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
    BJU Int. 2022;129:345-355.
    PubMed     Abstract available

  32. PASCHEN U, Sturtz S, Fleer D, Lampert U, et al
    Assessment of prostate-specific antigen screening: an evidence-based report by the German Institute for Quality and Efficiency in Health Care.
    BJU Int. 2022;129:280-289.
    PubMed     Abstract available

    February 2022
  33. BODAR YJL, Veerman H, Meijer D, de Bie K, et al
    Standardised Uptake Values as Determined on PSMA PET/CT is associated with Oncological Outcomes in Prostate Cancer Patients.
    BJU Int. 2022 Feb 15. doi: 10.1111/bju.15710.
    PubMed     Abstract available

  34. DASON S, Vertosick EA, Udo K, Sjoberg DD, et al
    Clinical utility of subclassifying positive surgical margins at radical prostatectomy.
    BJU Int. 2022;129:194-200.
    PubMed     Abstract available

  35. SORCE G, Stabile A, Luciano R, Motterle G, et al
    Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions.
    BJU Int. 2022;129:201-207.
    PubMed     Abstract available

    January 2022
  36. NOSSITER J, Morris M, Parry MG, Sujenthiran A, et al
    Impact of the Covid-19 pandemic on the diagnosis and treatment of men with prostate cancer.
    BJU Int. 2022 Jan 25. doi: 10.1111/bju.15699.
    PubMed     Abstract available

  37. ONG WL, Thangasamy I, Murphy D, Pritchard E, et al
    Large variation in conservative management for low-risk prostate cancer in Australia and New Zealand.
    BJU Int. 2022 Jan 25. doi: 10.1111/bju.15698.

  38. BRATT O
    Integrating magnetic resonance imaging and prostate-specific membrane antigen positron emission tomography/computed tomography results into prostate cancer treatment decision making.
    BJU Int. 2022;129:3-4.

  39. GRAY WK, Day J, Briggs TWR, Harrison S, et al
    An observational study of volume-outcome effects for robot-assisted radical prostatectomy in England.
    BJU Int. 2022;129:93-103.
    PubMed     Abstract available

    December 2021
  40. RANNIKKO A, Leht M, Mirtti T, Kenttamies A, et al
    Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: pilot study.
    BJU Int. 2021 Dec 27. doi: 10.1111/bju.15683.
    PubMed     Abstract available

  41. SOORIAKUMARAN P, Wilson C, Rombach I, Hassanali N, et al
    Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: TRoMbone trial.
    BJU Int. 2021 Dec 8. doi: 10.1111/bju.15669.
    PubMed     Abstract available

  42. VEERMAN H, Donswijk M, Bekers E, Olde Heuvel J, et al
    Clinical Characteristics of Primary Non-PSMA-Expressing Prostate Cancer on preoperative PSMA PET/CT.
    BJU Int. 2021 Dec 1. doi: 10.1111/bju.15664.
    PubMed     Abstract available

  43. Acute Urinary Retention and Cancer; Is It All About the Prostate?
    BJU Int. 2021;128:660.

  44. LENFANT L, Corrigan D, Beksac AT, Schwen Z, et al
    Learning curve analysis of single-port robot-assisted extraperitoneal prostatectomy using the cumulative sum (CUSUM) method.
    BJU Int. 2021;128:688-691.

  45. SANDAHL M, Pedersen BG, Ulhoi BP, Borre M, et al
    Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study.
    BJU Int. 2021;128:702-712.
    PubMed     Abstract available

  46. HENNES DMZB, Sewell J, Kerger M, Hovens CM, et al
    The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade.
    BJU Int. 2021;128 Suppl 3:45-51.
    PubMed     Abstract available

    November 2021
  47. JOHN JB, Pascoe J, Fowler S, Walton T, et al
    A nationwide trend away from radical prostatectomy for Gleason grade group 1 prostate cancer.
    BJU Int. 2021 Nov 26. doi: 10.1111/bju.15656.
    PubMed     Abstract available

  48. ROSENBERG JE, Jung JH, Lee H, Lee S, et al
    Posterior musculofascial reconstruction in robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer: a Cochrane Review.
    BJU Int. 2021 Nov 26. doi: 10.1111/bju.15657.
    PubMed     Abstract available

  49. LEE V, An Y, Park HS, Yu JB, et al
    Emergency Department Visits for Radiation Cystitis Among Patients with a Prostate Cancer History.
    BJU Int. 2021 Nov 22. doi: 10.1111/bju.15650.
    PubMed     Abstract available

  50. KANNAN A, Clouston D, Frydenberg M, Ilic D, et al
    Neuroendocrine cells in prostate cancer correlate with poor outcomes: A systematic review and meta-analysis.
    BJU Int. 2021 Nov 16. doi: 10.1111/bju.15647.
    PubMed     Abstract available

  51. HOFBAUER SL, Luger F, Harland N, Plage H, et al
    A Non-Inferiority Comparative Analysis of Micro-Ultrasound and MRI Targeted Biopsy in Men at Risk of Prostate Cancer.
    BJU Int. 2021 Nov 13. doi: 10.1111/bju.15635.
    PubMed     Abstract available

  52. IP CCK, Kealey J, Davis ID, Sengupta S, et al
    Impacts of the COVID-19 Pandemic on Early Detection of Prostate Cancer in Australia.
    BJU Int. 2021 Nov 9. doi: 10.1111/bju.15631.
    PubMed     Abstract available

  53. HEESTERMAN BL, van der Poel HG, Schoots IG, Mehra N, et al
    Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer.
    BJU Int. 2021 Nov 6. doi: 10.1111/bju.15632.
    PubMed     Abstract available

  54. PALUDO AO, Knijnik PG, Silva Neto B, Berger M, et al
    Initial experience with first postoperative day Foley catheter removal after robot-assisted radical prostatectomy.
    BJU Int. 2021;128:555-557.

  55. TULLY KH, Schulmeyer M, Hanske J, Reike MJ, et al
    Identification of patients at risk for biochemical recurrence after radical prostatectomy with intra-operative frozen section.
    BJU Int. 2021;128:598-606.
    PubMed     Abstract available

  56. ZHANG Z, Lampotang S, Yu Y, Acar YA, et al
    Attitude is everything: keep probe pitch neutral during side-fire prostate biopsy. A simulator study.
    BJU Int. 2021;128:615-624.
    PubMed     Abstract available

    October 2021
  57. HUYNH LM, Huang E, Towe M, Liang K, et al
    Evidence for integration of total and free testosterone levels in management of prostate cancer.
    BJU Int. 2021 Oct 30. doi: 10.1111/bju.15626.
    PubMed     Abstract available

  58. POULIOT F, Beauregard JM, Saad F, Trudel D, et al
    The 3TMPO study protocol: triple-tracer PET imaging of metastatic castration-resistant prostate cancer.
    BJU Int. 2021 Oct 21. doi: 10.1111/bju.15621.
    PubMed     Abstract available

  59. MARRA G, Calleris G, Marquis A, Oderda M, et al
    Reply to letter by Montorsi et al. Re: Marra et al. 'Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases'.
    BJU Int. 2021;128:524.

  60. MONTORSI F, Stabile A, Gandaglia G, Fossati N, et al
    Re: Marra et al. 'Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases'.
    BJU Int. 2021;128:523.

  61. GULDBAEK MV, Fode M, Jensen CFS, Sonksen J, et al
    'Case of the Month' from Herlev and Gentofte Hospital, Denmark: metastatic prostate cancer in a man with late-onset hypogonadism following testosterone-replacement therapy.
    BJU Int. 2021;128:428-430.

  62. KELLY R, Anton A, Wong S, Shapiro J, et al
    Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer.
    BJU Int. 2021;128 Suppl 1:18-26.
    PubMed     Abstract available

  63. CATHCART P, Ribeiro L, Moore C, Ahmed HU, et al
    Outcomes of the RAFT trial: robotic surgery after focal therapy.
    BJU Int. 2021;128:504-510.
    PubMed     Abstract available

    September 2021
  64. LIGHT A, Burns-Cox N, Maccormick A, John J, et al
    The diagnostic impact of UK regional variations in age-specific prostate-specific antigen guidelines.
    BJU Int. 2021;128:298-300.

    August 2021
  65. URIBE-LEWIS S, Uribe J, Bourke V, Deering C, et al
    Long-term survival after LDR Brachytherapy for Prostate Cancer: the Royal Surrey experience.
    BJU Int. 2021 Aug 27. doi: 10.1111/bju.15585.
    PubMed     Abstract available

  66. MOROTE J, Schwartzmann I, Celma A, Roche S, et al
    The current recommendation for the management of isolated high-grade prostatic intraepithelial neoplasia.
    BJU Int. 2021 Aug 10. doi: 10.1111/bju.15568.
    PubMed     Abstract available

  67. DOAN P, Graham P, Lahoud J, Remmers S, et al
    A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant?
    BJU Int. 2021 Aug 9. doi: 10.1111/bju.15554.
    PubMed     Abstract available

  68. ISRAEL B, Immerzeel J, van der Leest M, Hannink G, et al
    Clinical Implementation of Pre-biopsy MRI-Pathways for the Diagnosis of Prostate Cancer.
    BJU Int. 2021 Aug 6. doi: 10.1111/bju.15562.
    PubMed     Abstract available

  69. FDA approves a second PSMA targeting agent for PET imaging in men with prostate cancer.
    BJU Int. 2021;128:127-130.

    Multiparametric magnetic resonance imaging - a crucial imaging tool for considering and planning prostate cancer focal therapy.
    BJU Int. 2021;128:125-126.

  71. INOUE T, Sasaki T, Kato M, Masui S, et al
    Warning against second-generation antiandrogen for metastatic castration sensitive prostate cancer.
    BJU Int. 2021 Aug 1. doi: 10.1111/bju.15561.
    PubMed     Abstract available

  72. Chemotherapeutic treatment of MCRPC and non-MCRPC.
    BJU Int. 2021;128:153-154.

  73. TAMIR S, Hermann D, Margel D, Gavrielli S, et al
    Indications for prostate multiparametric magnetic resonance imaging: changes over 7 years in a single referral centre.
    BJU Int. 2021;128:165-167.

    July 2021
  74. BUELENS S, Poelaert F, Claeys T, De Bleser E, et al
    Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Study.
    BJU Int. 2021 Jul 21. doi: 10.1111/bju.15553.
    PubMed     Abstract available

  75. KAMRAN SC, Zietman AL
    Radiation Treatment in Prostate Cancer: Covering the Waterfront.
    BJU Int. 2021 Jul 17. doi: 10.1111/bju.15550.
    PubMed     Abstract available

  76. KREIS K, Horenkamp-Sonntag D, Schneider U, Zeidler J, et al
    Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer.
    BJU Int. 2021 Jul 9. doi: 10.1111/bju.15542.
    PubMed     Abstract available

  77. BENAFIF S, Ni Raghallaigh H, McGrowder E, Saunders EJ, et al
    The BARCODE1 Pilot: a feasibility study of using germline SNPs to target prostate cancer screening.
    BJU Int. 2021 Jul 2. doi: 10.1111/bju.15535.
    PubMed     Abstract available

  78. MOTTRIE A, Mazzone E, Wiklund P, Graefen M, et al
    Objective assessment of intraoperative skills for robot-assisted radical prostatectomy (RARP): results from the ERUS Scientific and Educational Working Groups Metrics Initiative.
    BJU Int. 2021;128:103-111.
    PubMed     Abstract available

  79. SINGH S, Sandhu P, Beckmann K, Santaolalla A, et al
    Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.
    BJU Int. 2021;128:72-78.
    PubMed     Abstract available

    June 2021
  80. MORI K, Mostafaei H, Sari Motlagh R, Pradere B, et al
    Systemic Therapies for Metastatic Hormone-Sensitive Prostate Cancer: Network Meta-Analysis.
    BJU Int. 2021 Jun 25. doi: 10.1111/bju.15507.
    PubMed     Abstract available

  81. BERTONCELLI TANAKA M, Sahota K, Burn J, Falconer A, et al
    Prostate cancer in transgender women: what does a urologist need to know?
    BJU Int. 2021 Jun 22. doi: 10.1111/bju.15521.
    PubMed     Abstract available

    Prostate cancer: the interplay between genetics and the environment.
    BJU Int. 2021;127:615-616.

  83. YAXLEY J
    Letter to the Editor BJUI in response to Montorsi et al.: Histological comparison between predictive value of preoperative 3-T multiparametric MRI and (68) Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node di
    BJU Int. 2021;127:747.

  84. DIRIE J, Mahesan T, Hart E, Janardanan S, et al
    Delivering safe and timely cancer care during COVID-19: lessons and successes from the transition period.
    BJU Int. 2021;127:633-635.

  85. TANDOGDU Z, Collins J, Shaw G, Rohn J, et al
    Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID-19) pandemic: an international accelerated consensus statement.
    BJU Int. 2021;127:729-741.
    PubMed     Abstract available

  86. DINNEEN E, Haider A, Grierson J, Freeman A, et al
    NeuroSAFE frozen section during robot-assisted radical prostatectomy: peri-operative and histopathological outcomes from the NeuroSAFE PROOF feasibility randomized controlled trial.
    BJU Int. 2021;127:676-686.
    PubMed     Abstract available

    May 2021
  87. EMMETT L, Subramaniam S, Joshua A, Crumbaker M, et al
    ENZA-p trial protocol: A randomised phase II trial using PSMA as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    BJU Int. 2021 May 24. doi: 10.1111/bju.15491.
    PubMed     Abstract available

  88. MEIJER D, van Leeuwen PJ, Donswijk ML, Boellaard TN, et al
    Predicting Early Outcomes in Intermediate and High Risk Prostate Cancer Patients using PSMA PET and MRI.
    BJU Int. 2021 May 24. doi: 10.1111/bju.15492.
    PubMed     Abstract available

  89. KNIPPER S, Tilki D, Graefen M, Maurer T, et al
    Early prostate cancer recurrence with PSMA PET positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProSTone, NCT04271579).
    BJU Int. 2021 May 22. doi: 10.1111/bju.15485.
    PubMed     Abstract available

  90. O'CALLAGHAN M, Papa N, Pase M, Frydenberg M, et al
    Patterns of care for prostate cancer treatment and improving outcomes - are national registries the answer?
    BJU Int. 2021 May 11. doi: 10.1111/bju.15366.

  91. Recent advances in the diagnosis and management of prostate cancer.
    BJU Int. 2021;127:518-519.

  92. URKMEZ A, Ward JF, Choi H, Troncoso P, et al
    Temporal learning curve of a multidisciplinary team for magnetic resonance imaging/transrectal ultrasonography fusion prostate biopsy.
    BJU Int. 2021;127:524-527.

  93. INOUE S, Hayashi T, Teishima J, Matsubara A, et al
    Longitudinal evaluation of the frequency of sexual intercourse and sexual activity in patients after nerve-sparing robot-assisted laparoscopic radical prostatectomy.
    BJU Int. 2021;127:560-566.
    PubMed     Abstract available

  94. TUTOLO M, Bruyneel L, Van der Aa F, Van Damme N, et al
    A novel tool to predict functional outcomes after robot-assisted radical prostatectomy and the value of additional surgery for incontinence.
    BJU Int. 2021;127:575-584.
    PubMed     Abstract available

  95. TIMM B, Farag M, Liodakis P, Angus D, et al
    Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
    BJU Int. 2021;127 Suppl 1:23-29.
    PubMed     Abstract available

  96. JOHN A, John H, Catterwell R, Selth LA, et al
    Primary Gleason grade and Gleason grade group at positive surgical margins: a systematic review and meta-analysis.
    BJU Int. 2021;127 Suppl 1:13-22.
    PubMed     Abstract available

    April 2021
  97. CHILUKURI S, Murthy V
    Adjuvant radiation for prostate cancer: Too early to abandon?
    BJU Int. 2021 Apr 9. doi: 10.1111/bju.15422.
    PubMed     Abstract available

  98. LUNDGREN PO, Kjellman A, Norming U, Gustafsson O, et al
    Association Between One-time Prostate-Specific Antigen (PSA) Test with Free/Total PSA and Prostate Cancer Mortality: A 30-year Prospective Cohort Study.
    BJU Int. 2021 Apr 3. doi: 10.1111/bju.15417.
    PubMed     Abstract available

  99. XU AJ, Taylor J, Gao T, Mihalcea R, et al
    TikTok and Prostate Cancer: Misinformation and Quality of Information using Validated Questionnaires.
    BJU Int. 2021 Apr 2. doi: 10.1111/bju.15403.
    PubMed     Abstract available

  100. GALFANO A, Secco S, Dell'Oglio P, Rha K, et al
    Retzius-sparing robot-assisted radical prostatectomy: early learning curve experience in three continents.
    BJU Int. 2021;127:412-417.
    PubMed     Abstract available

    March 2021
  101. GNANAPRAGASAM V, Barrett T, Pacey S, Warren A, et al
    Does modern Active surveillance offer an opportunity for new therapeutic strategies in early prostate cancer?
    BJU Int. 2021 Mar 27. doi: 10.1111/bju.15409.
    PubMed     Abstract available

  102. MARSHALL CH, Tunacao J, Danda V, Tsai HL, et al
    Reversing the effects of androgen deprivation therapy in men with metastatic castration resistant prostate cancer.
    BJU Int. 2021 Mar 25. doi: 10.1111/bju.15408.
    PubMed     Abstract available

  103. ANING JJ, Parry MG, van der Meulen J, Fowler S, et al
    How reliable is surgeon reported data? : A comparison of the British Association of Urological Surgeons radical prostatectomy audit with the National Prostate Cancer Audit Hospital Episode Statistic linked database.
    BJU Int. 2021 Mar 22. doi: 10.1111/bju.15399.
    PubMed     Abstract available

  104. WESSELS F, Schmitt M, Krieghoff-Henning E, Jutzi T, et al
    Deep learning approach to predict lymph node metastasis directly from primary tumor histology in prostate cancer.
    BJU Int. 2021 Mar 11. doi: 10.1111/bju.15386.
    PubMed     Abstract available

  105. ROSENBERG JE, Jung JH, Edgerton Z, Lee H, et al
    Retzius-sparing versus standard robotic assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.
    BJU Int. 2021 Mar 9. doi: 10.1111/bju.15385.
    PubMed     Abstract available

  106. DHIANTRAVAN N, Emmett L, Joshua AM, Pattison DA, et al
    UpFrontPSMA: A Randomised Phase 2 Study of Sequential (177) Lu-PSMA617 and Docetaxel versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer.
    BJU Int. 2021 Mar 7. doi: 10.1111/bju.15384.
    PubMed     Abstract available

  107. The FDA Approves PSMAtargeted Drug for PET Imaging in Men with Prostate Cancer.
    BJU Int. 2021;127:267-268.

  108. BARRETT T, Padhani AR, Patel A, Ahmed HU, et al
    Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting.
    BJU Int. 2021;127:304-306.

  109. NYBERG M, Sjoberg DD, Carlsson SV, Wilderang U, et al
    Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial.
    BJU Int. 2021;127:361-368.
    PubMed     Abstract available

    February 2021
  110. SOETERIK TFW, Hueting TA, Israel B, van Melick HHE, et al
    External validation of the MSKCC and Briganti Nomograms For Prediction of Lymph Node Involvement of Prostate Cancer Using Clinical Stage assessed by Magnetic Resonance Imaging.
    BJU Int. 2021 Feb 25. doi: 10.1111/bju.15376.
    PubMed     Abstract available

  111. DUNN J, Heathcote P, Chambers SK
    Prostate Cancer Survivorship Care: If not now, when?
    BJU Int. 2021 Feb 10. doi: 10.1111/bju.15358.
    PubMed     Abstract available

  112. ASLIM EJ, Law YXT, Fook-Chong SMC, Ho HSS, et al
    Defining prostate cancer size and treatment margin for focal therapy: does intra-lesional heterogeneity impact the performance of multiparametric MRI?
    BJU Int. 2021 Feb 4. doi: 10.1111/bju.15355.
    PubMed     Abstract available

  113. O'CONNOR LP, Lebastchi AH, Fasaye GA, Dikoglu E, et al
    'Case of the Month' from the National Cancer Institute, Bethesda, MD, USA: investigating genetic aberrations in a patient with high-risk prostate cancer.
    BJU Int. 2021;127:171-174.

  114. HUANG MM, Su ZT, Becker REN, Pavlovich CP, et al
    Complications after open and robot-assisted radical prostatectomy and association with postoperative opioid use: an analysis of data from the PREVENTER trial.
    BJU Int. 2021;127:190-197.
    PubMed     Abstract available

    January 2021
  115. ANDREWS JR, Hebert KJ, Boswell TC, Avant RA, et al
    Pubectomy and Urinary Reconstruction Provides Definitive Treatment of Urosymphyseal Fistula Following Prostate Cancer Treatment.
    BJU Int. 2021 Jan 5. doi: 10.1111/bju.15333.
    PubMed     Abstract available

  116. AHO T, Al-Hayek S, Winterbottom A, Koo B, et al
    'Case of the Month' from Cambridge University, UK: managing intractable bleeding from a 375 cc prostate in an anti-coagulated patient.
    BJU Int. 2021;127:37-40.

  117. World News.
    BJU Int. 2021;127:1-3.

  118. COVAS MOSCHOVAS M, Bhat S, Onol F, Rogers T, et al
    Early outcomes of single-port robot-assisted radical prostatectomy: lessons learned from the learning-curve experience.
    BJU Int. 2021;127:114-121.
    PubMed     Abstract available

    December 2020
  119. LONERGAN PE, Vertosick EA, Assel M, Sjoberg DD, et al
    Prospective validation of microseminoprotein-beta added to the 4Kscore in predicting high-grade prostate cancer in an international multi-center cohort.
    BJU Int. 2020 Dec 11. doi: 10.1111/bju.15320.
    PubMed     Abstract available

  120. MURPHY C, de Laine C, Macaulay M, Fader M, et al
    A multicentre exploratory study of the impact of urinary incontinence in the 6 weeks after catheter removal following radical prostatectomy.
    BJU Int. 2020;126:667-669.

  121. SUH J, Yoo S, Park J, Cho SY, et al
    Development and validation of an explainable artificial intelligence-based decision-supporting tool for prostate biopsy.
    BJU Int. 2020;126:694-703.
    PubMed     Abstract available

    November 2020
  122. MONTORSI F, Gandaglia G, Fossati N, Deho F, et al
    Re: Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
    BJU Int. 2020 Nov 29. doi: 10.1111/bju.15308.
    PubMed     Abstract available

  123. EGEVAD L, Delahunt B, Bostwick DG, Cheng L, et al
    Prostate Cancer Grading, Time To Go Back To the Future.
    BJU Int. 2020 Nov 18. doi: 10.1111/bju.15298.
    PubMed     Abstract available

  124. NORRIS JM, Carmona Echeverria LM, Simpson BS, Ball R, et al
    Conspicuity of cribriform prostate cancer on multiparametric magnetic resonance imaging: the jury is still out.
    BJU Int. 2020 Nov 13. doi: 10.1111/bju.15295.
    PubMed     Abstract available

  125. POULSON M, Helrich S, Kenzik K, Dechert T, et al
    The Impact of Residential Segregation on Prostate Cancer Diagnosis and Treatment.
    BJU Int. 2020 Nov 9. doi: 10.1111/bju.15293.
    PubMed     Abstract available

  126. QIU X, Li Y, Chen M, Xu L, et al
    Retzius-sparing robot-assisted radical prostatectomy improves early recovery of urinary continence: a randomized, controlled, single-blind trial with a 1-year follow-up.
    BJU Int. 2020;126:633-640.
    PubMed     Abstract available

  127. FENG T, Heulitt G, Lee JJ, Liao M, et al
    Randomised comparison of techniques for control of the dorsal venous complex during robot-assisted laparoscopic radical prostatectomy.
    BJU Int. 2020;126:586-594.
    PubMed     Abstract available

  128. EDISON MA, Connor MJ, Miah S, El-Husseiny T, et al
    Understanding virtual urology clinics: a systematic review.
    BJU Int. 2020;126:536-546.
    PubMed     Abstract available

  129. LEE AYM, Yang XY, Lee HJ, Law YM, et al
    Multiparametric MRI-ultrasonography software fusion prostate biopsy: initial results using a stereotactic robotic-assisted transperineal prostate biopsy platform comparing systematic vs targeted biopsy.
    BJU Int. 2020;126:568-576.
    PubMed     Abstract available

    October 2020
  130. SCHOOTS IG, Padhani AR
    Risk-adapted biopsy decision based on prostate MRI and PSA-density for enhanced biopsy avoidance in first prostate cancer diagnostic work-up.
    BJU Int. 2020 Oct 21. doi: 10.1111/bju.15277.
    PubMed     Abstract available

  131. FUJIHARA A, Iwata T, Shakir A, Tafuri A, et al
    Multiparametric Magnetic Resonance Imaging Facilitates Reclassification During Active Surveillance for Prostate Cancer.
    BJU Int. 2020 Oct 11. doi: 10.1111/bju.15272.
    PubMed     Abstract available

  132. EXTERKATE L, Peters M, Somford DM, Vergunst H, et al
    Functional and oncological outcomes of salvage cryosurgery for radiorecurrent prostate cancer.
    BJU Int. 2020 Oct 11. doi: 10.1111/bju.15269.
    PubMed     Abstract available

  133. NAIR SM, Hatiboglu G, Relle J, Hetou K, et al
    MRI-Guided Transurethral Ultrasound Ablation in Patients with Localized Prostate Cancer: Three Year Outcomes of a Prospective Phase I Study.
    BJU Int. 2020 Oct 9. doi: 10.1111/bju.15268.
    PubMed     Abstract available

  134. WHISH-WILSON T, Costello D, Finch S, Sutherland T, et al
    Funding of prostate magnetic resonance imaging leads to fewer biopsies and potential savings to health systems in the management of prostate cancer.
    BJU Int. 2020 Oct 6. doi: 10.1111/bju.15231.
    PubMed     Abstract available

    September 2020
  135. STROMAN L, Cathcart P, Lamb A, Challacombe B, et al
    A cross-section of UK prostate cancer diagnostics during the COVID-19 era - a shifting paradigm?
    BJU Int. 2020 Sep 27. doi: 10.1111/bju.15259.
    PubMed     Abstract available

  136. DIAO W, Cao Y, Su D, Jia Z, et al
    (68) Ga-prostate-specific membrane antigen tracers can alter the management of more than half of prostate cancer patients with biochemical recurrence.
    BJU Int. 2020 Sep 26. doi: 10.1111/bju.15257.
    PubMed     Abstract available

  137. MADAN RA, Karzai FH, Al Harthy M, Petrylak DP, et al
    Cabozantinib plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer.
    BJU Int. 2020 Sep 24. doi: 10.1111/bju.15227.
    PubMed     Abstract available

  138. MARVASO G, Montesano M, Corrao G, De Angelis SP, et al
    Adjuvant radiotherapy in node positive prostate cancer patients: a debate still on. when, for whom?
    BJU Int. 2020 Sep 24. doi: 10.1111/bju.15228.
    PubMed     Abstract available

  139. GOLDBERG H, Glicksman R, Woon D, Hoffman A, et al
    Can postreatment free psa ratio be used to predict adverse outcomes in recurrent prostate cancer?
    BJU Int. 2020 Sep 14. doi: 10.1111/bju.15236.
    PubMed     Abstract available

  140. ODERDA M, Diamand R, Albisinni S, Calleris G, et al
    Indications and complications of pelvic lymph node dissection for prostate cancer: are currently available nomograms accurate to predict lymph node invasion?
    BJU Int. 2020 Sep 1. doi: 10.1111/bju.15220.
    PubMed     Abstract available

  141. CAHILL D
    How the Martini-Klinik handled prostate surgery during COVID-19.
    BJU Int. 2020;126:E1.

  142. COWAN T, Baker E, McCray G, Reeves F, et al
    Detection of clinically significant cancer in the anterior prostate by transperineal biopsy.
    BJU Int. 2020;126 Suppl 1:33-37.
    PubMed     Abstract available

  143. FRANKLIN A, Gianduzzo T, Yaxley J, Kua B, et al
    Use of a trizonal schema to assess targeting accuracy in prostatic fusion biopsy.
    BJU Int. 2020;126 Suppl 1:6-11.
    PubMed     Abstract available

  144. ROCCO B, Sighinolfi MC, Cimadamore A, Reggiani Bonetti L, et al
    Digital frozen section of the prostate surface during radical prostatectomy: a novel approach to evaluate surgical margins.
    BJU Int. 2020;126:336-338.

    August 2020
  145. VEERMAN H, van Leeuwen PJ, Bekers E, van der Poel HG, et al
    Case of the month from the Netherlands Cancer Institute, Amsterdam: how to differentiate between benign and malignant prostatic cysts.
    BJU Int. 2020;126:240-244.

  146. ZHOU X, Fu B, Zhang C, Liu W, et al
    Transvesical robot-assisted radical prostatectomy: initial experience and surgical outcomes.
    BJU Int. 2020;126:300-308.
    PubMed     Abstract available

  147. NEALE A, Stroman L, Kum F, Jabarkhyl D, et al
    Targeted and systematic cognitive freehand-guided transperineal biopsy: is there still a role for systematic biopsy?
    BJU Int. 2020;126:280-285.
    PubMed     Abstract available

    July 2020
    Prostate cancer screening and treatment: where have we come from and where are we going?
    BJU Int. 2020 Jul 27. doi: 10.1111/bju.15153.
    PubMed     Abstract available

  149. UCHIMOTO T, Komura K, Fukuokaya W, Kimura T, et al
    Risk Stratification for the Prediction of Overall Survival Could Assists Treatment Decision Making at the Diagnosis of Castration-Resistant Prostate Cancer - a Multicenter Collaborative Study in Japan.
    BJU Int. 2020 Jul 23. doi: 10.1111/bju.15187.
    PubMed     Abstract available

  150. DUNN J, Green A, Ralph N, Newton RU, et al
    Prostate Cancer Survivorship Essentials Framework: Guidelines for Practitioners.
    BJU Int. 2020 Jul 5. doi: 10.1111/bju.15159.
    PubMed     Abstract available

  151. CHECCUCCI E, De Cillis S, Pecoraro A, Peretti D, et al
    Single-port robot-assisted radical prostatectomy: a systematic review and pooled analysis of the preliminary experiences.
    BJU Int. 2020;126:55-64.
    PubMed     Abstract available

  152. TAMHANKAR AS, El-Taji O, Vasdev N, Foley C, et al
    The clinical and financial implications of a decade of prostate biopsies in the NHS: analysis of Hospital Episode Statistics data 2008-2019.
    BJU Int. 2020;126:133-141.
    PubMed     Abstract available

  153. BERRY B, Parry MG, Sujenthiran A, Nossiter J, et al
    Comparison of complications after transrectal and transperineal prostate biopsy: a national population-based study.
    BJU Int. 2020;126:97-103.
    PubMed     Abstract available

    June 2020
  154. MATTI B, Lyndon M, Zargar-Shoshtari K
    Ethnic and Socioeconomic disparities in Prostate Cancer Screening - Lessons from New Zealand.
    BJU Int. 2020 Jun 29. doi: 10.1111/bju.15155.
    PubMed     Abstract available

  155. CHEN MY, Franklin A, Yaxley J, Gianduzzo T, et al
    Solitary rib lesions showing PSMA uptake in pre-treatment staging (68) Ga-PSMA-11 PET scans for men with prostate cancer: benign or malignant?
    BJU Int. 2020 Jun 27. doi: 10.1111/bju.15152.
    PubMed     Abstract available

  156. ANTON A, Kamel Hasan O, Ballok Z, Bowden P, et al
    Use of PSMA PET/CT in Response Assessment Following Upfront Chemohormonal Therapy in Metastatic Prostate Cancer.
    BJU Int. 2020 Jun 24. doi: 10.1111/bju.15151.
    PubMed     Abstract available

  157. MAYOR N, Sathianathen NJ, Buteau J, Koschel S, et al
    PSMA Theranostics in advanced prostate cancer: an evolving option.
    BJU Int. 2020 Jun 19. doi: 10.1111/bju.15143.
    PubMed     Abstract available

  158. TOMER A, Nieboer D, Roobol MJ, Bjartell A, et al
    Personalized Biopsy Schedules Based on Risk of Gleason Upgrading for Low-Risk Prostate Cancer Active Surveillance Patients.
    BJU Int. 2020 Jun 12. doi: 10.1111/bju.15136.
    PubMed     Abstract available

  159. PFISTER D, Haidl F, Nestler T, Verburg F, et al
    (68) Ga-PSMA-PET/CT helps to select patients for salvage radical prostatectomy with local recurrence after primary radiotherapy for prostate cancer.
    BJU Int. 2020 Jun 12. doi: 10.1111/bju.15135.
    PubMed     Abstract available

  160. FRANKLIN A, Yaxley WJ, Raveenthiran S, Coughlin G, et al
    Histological comparison between predictive value of pre-operative 3T multiparametric MRI and (68) Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
    BJU Int. 2020 Jun 10. doi: 10.1111/bju.15134.
    PubMed     Abstract available

  161. AKAKURA K, Bolton D, Grillo V, Mermod N, et al
    Not All Prostate Cancer is the Same - Patient perceptions: An Asia-Pacific study.
    BJU Int. 2020 Jun 10. doi: 10.1111/bju.15129.
    PubMed     Abstract available

    Low-dose-rate brachytherapy for prostate cancer stands the test of time - the Swiss experience.
    BJU Int. 2020;125:750-751.

  163. SEETHARAM BHAT KR, Moschovas MC, Onol FF, Sandri M, et al
    Trends in clinical and oncological outcomes of robot-assisted radical prostatectomy before and after the 2012 US Preventive Services Task Force recommendation against PSA screening: a decade of experience.
    BJU Int. 2020;125:884-892.
    PubMed     Abstract available

    May 2020
  164. MARRA G, Zhuang J, Beltrami M, Calleris G, et al
    Transperineal free-hand mpMRI fusion targeted biopsies under local anesthesia for Prostate Cancer Diagnosis: a multicenter prospective study of 1,014 cases.
    BJU Int. 2020 May 26. doi: 10.1111/bju.15121.
    PubMed     Abstract available

  165. POPERT R, Kum F, MacAskill F, Stroman L, et al
    Our First Month of Delivering the Prostate Cancer Diagnostic Pathway within the Limitations of COVID-19 Using Local Anaesthetic Transperineal Biopsy.
    BJU Int. 2020 May 26. doi: 10.1111/bju.15120.
    PubMed     Abstract available

  166. WURNSCHIMMEL C, Maurer T, Knipper S, von Breunig F, et al
    Martini-Klinik experience on prostate cancer surgery during the early phase of COVID-19.
    BJU Int. 2020 May 18. doi: 10.1111/bju.15115.
    PubMed     Abstract available

  167. JOSHI A, Roberts MJ, Alinezhad S, Williams ED, et al
    Challenges, applications and future directions of precision medicine in prostate cancer - the role of organoids and patient-derived xenografts.
    BJU Int. 2020 May 8. doi: 10.1111/bju.15103.
    PubMed     Abstract available

  168. SCHWEN ZR, Mamawala M, Tosoian JJ, Druskin SC, et al
    Prostate Health Index and Multiparametric MRI to Predict Prostate Cancer Grade Reclassification in Active Surveillance.
    BJU Int. 2020 May 4. doi: 10.1111/bju.15101.
    PubMed     Abstract available

  169. SHAPIRO DD, Ward JF, Lim AH, Nogueras-Gonzalez GM, et al
    Comparing confirmatory biopsy outcomes between MRI-targeted biopsy and standard systematic biopsy among men being enrolled in prostate cancer active surveillance.
    BJU Int. 2020 May 1. doi: 10.1111/bju.15100.
    PubMed     Abstract available

  170. HAEUSER L, Nguyen DD, Trinh QD
    Prostate cancer and kidney transplantation - exclusion or co-existence?
    BJU Int. 2020;125:628-629.

  171. NABI J
    The provision of comfort: addressing barriers to sleep in prostate cancer.
    BJU Int. 2020;125:627-628.

  172. SIGHINOLFI MC, Eissa A, Spandri V, Puliatti S, et al
    Positive surgical margin during radical prostatectomy: overview of sampling methods for frozen sections and techniques for the secondary resection of the neurovascular bundles.
    BJU Int. 2020;125:656-663.
    PubMed     Abstract available

  173. YAMAMOTO A, Kato M, Hattori K, Naito Y, et al
    Propensity score-matched comparison of docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant intraductal carcinoma of the prostate.
    BJU Int. 2020;125:702-708.
    PubMed     Abstract available

    April 2020
  174. SEYMOUR ZA, Hamstra DA, Daignault-Newton S, Bosch W, et al
    Long-term Follow-up After Radiotherapy for Prostate Cancer with and without Rectal Hydrogel Spacer: A Pooled Prospective Evaluation of Bowel Associated Quality of Life.
    BJU Int. 2020 Apr 25. doi: 10.1111/bju.15097.
    PubMed     Abstract available

  175. HEIDENREICH A, Bludau M, Bruns C, Nestler T, et al
    Pelvic exenteration surgery in patients with locally advanced castration-naive and castration-resistant, symptomatic prostate cancer.
    BJU Int. 2020 Apr 22. doi: 10.1111/bju.15088.
    PubMed     Abstract available

  176. NORRIS JM, Carmona Echeverria LM, Simpson BS, Allen C, et al
    Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: High Gleason Grade and Increased Tumour Volume are Not the Only Important Histopathological Features.
    BJU Int. 2020 Apr 22. doi: 10.1111/bju.15085.
    PubMed     Abstract available

  177. MANNAERTS CK, Engelbrecht MRW, Postema AW, van Kollenburg RAA, et al
    Detection of clinically significant prostate cancer in biopsy-naive men: Head-to-head comparison of systematic biopsy, multiparametric MRI- and contrast ultrasound dispersion imaging-targeted biopsy.
    BJU Int. 2020 Apr 21. doi: 10.1111/bju.15093.
    PubMed     Abstract available

  178. SZARVAS T, Csizmarik A, Fazekas T, Huttl A, et al
    Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
    BJU Int. 2020 Apr 20. doi: 10.1111/bju.15086.
    PubMed     Abstract available

  179. BORNO HT, Zhang S, Bakke B, Bell A, et al
    Disparities and Online Health Information: YouTube and Prostate Cancer Clinical Trials.
    BJU Int. 2020 Apr 10. doi: 10.1111/bju.15081.
    PubMed     Abstract available

  180. ORRASON AW, Westerberg M, Garmo H, Franck Lissbrant I, et al
    Changes in treatment and mortality in men with locally advanced prostate cancer between 2000-2016. Nationwide, population-based study in Sweden.
    BJU Int. 2020 Apr 10. doi: 10.1111/bju.15077.
    PubMed     Abstract available

    Estimating the threat posed by prostate cancer.
    BJU Int. 2020;125:480-481.

  182. STONIER T, Cathcart P
    Further evidence that surgery after focal therapy for prostate cancer is safe.
    BJU Int. 2020;125:481-482.

  183. TUGCU V, Eksi M, Sahin S, Colakoglu Y, et al
    Robot-assisted radical perineal prostatectomy: a review of 95 cases.
    BJU Int. 2020;125:573-578.
    PubMed     Abstract available

  184. ROCCO B, Sighinolfi MC, Bertoni L, Spandri V, et al
    Real-time assessment of surgical margins during radical prostatectomy: a novel approach that uses fluorescence confocal microscopy for the evaluation of peri-prostatic soft tissue.
    BJU Int. 2020;125:487-489.

  185. BRYANT RJ, Oxley J, Young GJ, Lane JA, et al
    The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression.
    BJU Int. 2020;125:506-514.
    PubMed     Abstract available

  186. HERRERA-CACERES JO, Nason GJ, Salgado-Sanmamed N, Goldberg H, et al
    Salvage radical prostatectomy following focal therapy: functional and oncological outcomes.
    BJU Int. 2020;125:525-530.
    PubMed     Abstract available

  187. WAJSWOL E, Winoker JS, Anastos H, Falagario U, et al
    A cohort of transperineal electromagnetically tracked magnetic resonance imaging/ultrasonography fusion-guided biopsy: assessing the impact of inter-reader variability on cancer detection.
    BJU Int. 2020;125:531-540.
    PubMed     Abstract available

    March 2020
  188. OSSES DF, Drost FH, Verbeek JFM, Luiting HB, et al
    Prostate cancer upgrading with serial prostate MRI scans and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?
    BJU Int. 2020 Mar 31. doi: 10.1111/bju.15065.
    PubMed     Abstract available

  189. AHLERING TE, Huynh LM, Towe M, See K, et al
    Testosterone replacement therapy reduces biochemical recurrence post-radical prostatectomy.
    BJU Int. 2020 Mar 2. doi: 10.1111/bju.15042.
    PubMed     Abstract available

  190. TEOH JY, Chiong E, Ng CF
    Can artificial intelligence optimize case selection for hemi-gland ablation?
    BJU Int. 2020;125:333-334.

  191. GLASER ZA, Rais-Bahrami S
    Magnetic resonance imaging as a personalised tool to safely avoid prostate biopsy.
    BJU Int. 2020;125:335-336.

  192. FRANCOLINI G, Jereczek-Fossa BA, Di Cataldo V, Simontacchi G, et al
    Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series.
    BJU Int. 2020;125:417-425.
    PubMed     Abstract available

    February 2020
  193. ALLOTT EH, Csizmadi I, Howard LE, Muller RL, et al
    Statin use and longitudinal changes in prostate volume; results from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
    BJU Int. 2020;125:226-233.
    PubMed     Abstract available

  194. HANSEN NL, Barrett T, Lloyd T, Warren A, et al
    Optimising the number of cores for magnetic resonance imaging-guided targeted and systematic transperineal prostate biopsy.
    BJU Int. 2020;125:260-269.
    PubMed     Abstract available

  195. SAAD M, Moschini M, Stabile A, Macek P, et al
    Long-term functional and oncological outcomes of nerve-sparing and prostate capsule-sparing cystectomy: a single-centre experience.
    BJU Int. 2020;125:253-259.
    PubMed     Abstract available

  196. KUM F, Elhage O, Maliyil J, Wong K, et al
    Initial outcomes of local anaesthetic freehand transperineal prostate biopsies in the outpatient setting.
    BJU Int. 2020;125:244-252.
    PubMed     Abstract available

    January 2020
  197. ONOL FF, Bhat S, Moschovas M, Rogers T, et al
    Comparison of outcomes of salvage robot-assisted laparoscopic prostatectomy for post-primary radiation vs focal therapy.
    BJU Int. 2020;125:103-111.
    PubMed     Abstract available

  198. KHAN-RUF S, Thurairajah R, Khan MS, Bultitude M, et al
    Digging through a genomic goldmine: defining the optimum upper urinary tract surveillance strategy for Lynch syndrome.
    BJU Int. 2020;125:6-7.

    August 2019
  199. SALTER CA, Mulhall JP
    Guideline of Guidelines: Testosterone Replacement Therapy for Testosterone Deficiency.
    BJU Int. 2019 Aug 17. doi: 10.1111/bju.14899.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.